Clinical Trials Logo

Cocaine Dependence clinical trials

View clinical trials related to Cocaine Dependence.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02134002 Withdrawn - Cocaine Dependence Clinical Trials

A PET Exploration of the Mechanism of Action of Dopamine Beta-hydroxylase Inhibition in Cocaine Addicts

RAPID
Start date: June 2014
Phase: Phase 4
Study type: Interventional

This study represents a randomized, double blind placebo-controlled trial. Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization. Main outcome criteria will be evaluated during two TEP imaging sessions with 11Craclopride, before and after stimulation by methylphenidate, 8 to 15 days after randomization.

NCT ID: NCT02003664 Withdrawn - Cocaine Dependence Clinical Trials

A Study of Baclofen ER

CURE
Start date: November 2013
Phase: Phase 2
Study type: Interventional

This is a Phase II, randomized, double-blind, placebo-controlled study that will examine the efficacy of extended-release baclofen (Baclofen ER) for the treatment of cocaine dependence. The primary study outcome will be urines positive for benzoylecgonine (BE), a metabolite of cocaine, submitted during outpatient treatment (12-week) and follow-up (12-week). To examine brain mechanisms of relapse/recovery, participants will complete fMRI sessions before, during, and after treatment. Brain responses to specific probes of reward and inhibition will be used as biomarkers predicting drug use during and after the treatment.

NCT ID: NCT01741376 Withdrawn - Nicotine Dependence Clinical Trials

Progesterone and Atomoxetine for Cocaine Cessation

Start date: November 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the role of progesterone (a hormone found in both men and women) on stopping cocaine use. The study will examine whether the medication, in combination with behavior therapy will decrease cocaine use, cigarette smoking, withdrawal symptoms, impulsivity and stress.

NCT ID: NCT01715051 Withdrawn - Cocaine Dependence Clinical Trials

D-Serine for Cocaine Dependence Pilot

STED-CD
Start date: February 2014
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to collect pilot data on the efficacy of D-serine, relative to placebo, as a cocaine dependence treatment. Secondary objectives include evaluating D-serine, relative to placebo, on: 1. safety in treating cocaine-dependent adults and 2. tolerability.

NCT ID: NCT01406522 Withdrawn - Cocaine Dependence Clinical Trials

Tacrine Effects on Cocaine Self-Administration and Pharmacokinetics

Start date: October 2012
Phase: Phase 2
Study type: Interventional

No medications are currently available for treatment of psychostimulant addiction, a compulsive preoccupation with use of cocaine and related compounds. Tacrine, a medication that is currently prescribed for Alzheimer's disease, can decrease the amount of cocaine injections that laboratory animals choose to inject by vein. This project will determine if tacrine can also decrease cocaine-motivated behavior for human subjects in a laboratory setting.

NCT ID: NCT01143857 Withdrawn - Cocaine Dependence Clinical Trials

Human Behavioral Pharmacology Laboratory Study of Varenicline's Impact on Cocaine Reinforcement

Start date: June 2010
Phase: Phase 2
Study type: Interventional

Cocaine use, abuse and dependence is a public health problem that is directly responsible for hundreds of billions of dollars in health care expenditures per year. Relapse rates to cocaine use are high, creating a pressing need to develop effective therapies for cocaine dependence. The proposed research will focus on investigating the determinants and consequences of cocaine dependence via measurement of physiological, behavioral and subjective effects of acute doses of cocaine in healthy non-drug dependent human volunteers in the laboratory, and through examination of the effects of pharmacotherapies on the above effects of cocaine. This study will examine cocaine-derived reinforcement under week-long sub-chronic varenicline (Chantix) dosing, and under placebo conditions. The study is a within-subjects crossover design using 24 subjects. Subjects will be screened and consented into the study at the Treatment Research Center (TRC). Study visits where behavioral and physiological outcome data will be obtained will be conducted at the Clinical and Translational Research Center (CTRC) of the Hospital of the University of Pennsylvania. Subjects will be outpatients for this trial, with CTRC sessions scheduled at least one week apart.